This Study is a single arm, open label, multicenter phase III clinical trial to evaluate the safety and efficacy of VC004 in patients with locally advanced/metastatic solid tumors.
All subjects or legal representatives are willing and able to sign ICF approved by the ethics committee before starting any screening procedures；
Male or female, age ≥12 years old;
Patients have undergone major surgery within 4 weeks prior to the first dose or are expected to undergo major surgery during the trial (excluding vascular access establishment procedures, biopsy procedures);
Adverse reactions caused by previous treatment have not recovered to ≤1 grade (evaluated by the investigator);
Patients had been treated with a strong CYP3A inhibitor or inducer within 7 days prior to the first administration of the study drug.
Single group
VC004 Capsules
DrugVC004 Capsules BID
Objective response rate(ORR)
Click on the lead sponsor to view all of their trials.
